Background： Increased serurn autoantibodies against interleukin-2 （anti-IL-2 autoantibodies） were reported in patients with systemic lupus crythematosus （SLE） and in patients receiving IL-2 therapy. This study ai...Background： Increased serurn autoantibodies against interleukin-2 （anti-IL-2 autoantibodies） were reported in patients with systemic lupus crythematosus （SLE） and in patients receiving IL-2 therapy. This study aimed to explore the clinical relevance of serum anti-IL-2 autoantibodies and the interactions between low-dose IL-2 therapy and serum anti-IL-2 autoantibodies. Methods： Serum samples were collected from 152 SLE patients and 100 age- and gender-matched healthy controls （HCs）. Among them, 75 SLE patients were followed tip for 10 weeks, and all of them were treated with corticosteroids, antimalarials, and/or immunosuppressants. Forty-six out of the 75 SLE patients received low-dose IL-2 therapy additionally. Clinical and laboratory parameters were collected at baseline and week 10. Serum anti-lL-2 autoantibodies were determined by enzyme-linked immunosorbent assay. Results： Compared with HCs, median levels and positive rates of sernm anti-IL-2 autoantibodics were higher in SLE patients （32.58 [23.63, 45.23] arbitrary unit [AU] vs. 37.54 [27.88, 60.74] AU, P- 0.006, and 5.0% vs. 18.4%, P = 0.002, respectively）. Compared to those without the corresponding disorders, serum anti-IL-2 autoantibody was increased in patients with alopecia （49.79 [36.06, 64.95] AU vs. 35.06 [25.40, 58.46] AU, P = 0.033）, but it was decreased in those with lupus nephritis （31.71 [22.60, 43.25] AU vs. 44.15 [31.43, 68.52] AU, P= 0.001 ）. Moreover, serum anti-I L-2 autoantibody was positively correlated with serum IgA （r= 0.229, P = 0.005）, total lgG （r= 0.327, P 〈 0.001 ）, and total lgM （r=0.164, P = 0.050）. Treatment with exogenous IL-2 was not significantly associated with serum anti-IL-2 autoantibody. In addition, no significant difference was found in serum anti-lL-2 autoantibody between responders and nonresponders to low-dose I L-2 therapy. Conclusions： Serum anti-lL-2 autoantibody was increased and associated with disease severity in SLE. Exogenous low-dose IL-2 did not significantly induce anti-IL-2 autoantibody production.展开更多
基金This study was supported by grants from the National Natural Science Foundation of China （No. 31530020, No. 81471601, and No. 81671602） and the Beijing Nova Program （No. Z 171100001117025）.
文摘Background： Increased serurn autoantibodies against interleukin-2 （anti-IL-2 autoantibodies） were reported in patients with systemic lupus crythematosus （SLE） and in patients receiving IL-2 therapy. This study aimed to explore the clinical relevance of serum anti-IL-2 autoantibodies and the interactions between low-dose IL-2 therapy and serum anti-IL-2 autoantibodies. Methods： Serum samples were collected from 152 SLE patients and 100 age- and gender-matched healthy controls （HCs）. Among them, 75 SLE patients were followed tip for 10 weeks, and all of them were treated with corticosteroids, antimalarials, and/or immunosuppressants. Forty-six out of the 75 SLE patients received low-dose IL-2 therapy additionally. Clinical and laboratory parameters were collected at baseline and week 10. Serum anti-lL-2 autoantibodies were determined by enzyme-linked immunosorbent assay. Results： Compared with HCs, median levels and positive rates of sernm anti-IL-2 autoantibodics were higher in SLE patients （32.58 [23.63, 45.23] arbitrary unit [AU] vs. 37.54 [27.88, 60.74] AU, P- 0.006, and 5.0% vs. 18.4%, P = 0.002, respectively）. Compared to those without the corresponding disorders, serum anti-IL-2 autoantibody was increased in patients with alopecia （49.79 [36.06, 64.95] AU vs. 35.06 [25.40, 58.46] AU, P = 0.033）, but it was decreased in those with lupus nephritis （31.71 [22.60, 43.25] AU vs. 44.15 [31.43, 68.52] AU, P= 0.001 ）. Moreover, serum anti-I L-2 autoantibody was positively correlated with serum IgA （r= 0.229, P = 0.005）, total lgG （r= 0.327, P 〈 0.001 ）, and total lgM （r=0.164, P = 0.050）. Treatment with exogenous IL-2 was not significantly associated with serum anti-IL-2 autoantibody. In addition, no significant difference was found in serum anti-lL-2 autoantibody between responders and nonresponders to low-dose I L-2 therapy. Conclusions： Serum anti-lL-2 autoantibody was increased and associated with disease severity in SLE. Exogenous low-dose IL-2 did not significantly induce anti-IL-2 autoantibody production.
